10-Q: Walgreens Boots Alliance Reports Q2 2025 Results, Announces Merger Agreement and Dividend Suspension

Walgreens Boots Alliance (WBA) reported its Q2 2025 results, highlighted by a merger agreement with Blazing Star Parent, LLC, and the suspension of its quarterly dividend.

Summary

• Walgreens Boots Alliance reported a net loss attributable to WBA of $2.853 billion, or $3.30 per share, for the three months ended February 28, 2025, compared to a net loss of $5.908 billion, or $6.85 per share, in the prior year.
• Sales increased by 4.1% to $38.588 billion.
• The company entered into a merger agreement with Blazing Star Parent, LLC, where shareholders will receive $11.45 per share in cash and a Divested Asset Proceed Right.
• The Board of Directors suspended the quarterly cash dividend to stockholders.
• The company recognized a goodwill impairment charge of $1.5 billion related to VillageMD and $2.0 billion related to U.S. Retail Pharmacy.
• The company early settled certain variable prepaid forward (VPF) derivative contracts, resulting in a gain of $955 million.
• The company is implementing a Footprint Optimization Program, planning to close approximately 900 to 1,000 stores by the end of fiscal 2027.
• The company sold shares of BrightSpring Health Services, reducing its ownership percentage.
• The company is defending a number of claims, lawsuits, and investigations alleging that the company's retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process.

Sentiment

Score: 4

Explanation: The announcement includes both positive and negative elements. The merger agreement provides some certainty, but the dividend suspension and net loss are concerning.

Positives

• Sales increased by 4.1% to $38.588 billion.
• The company early settled certain variable prepaid forward (VPF) derivative contracts, resulting in a gain of $955 million.
• The U.S. Healthcare segment showed improvement in adjusted operating income.
• The company is implementing a Footprint Optimization Program, planning to close approximately 900 to 1,000 stores by the end of fiscal 2027, which is expected to improve cash flow.
• Comparable pharmacy sales increased 12.2 percent for the three months ended February 28, 2025, driven by higher branded drug inflation and prescription volume.

Negatives

• Walgreens Boots Alliance reported a net loss attributable to WBA of $2.853 billion, or $3.30 per share, for the three months ended February 28, 2025.
• The Board of Directors suspended the quarterly cash dividend to stockholders.
• The company recognized a goodwill impairment charge of $1.5 billion related to VillageMD and $2.0 billion related to U.S. Retail Pharmacy.
• Retail sales decreased by 5.5 percent for the three months ended February 28, 2025.
• The company is defending a number of claims, lawsuits, and investigations alleging that the company's retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process.

Risks

• The merger with Blazing Star Parent, LLC is subject to regulatory approvals and other conditions, and may not be completed.
• The company's cash requirements and ability to generate cash flow may be adversely affected by opioid-related claims and litigation settlements.
• Adverse global macroeconomic conditions, including inflation, high interest rates, and supply chain disruptions, could impact the company's operations and financial results.
• The company is subject to extensive regulation by national, state and local government agencies in the U.S. and other countries in which it operates.
• The company is defending a number of claims, lawsuits, and investigations alleging that the company's retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process.

Future Outlook

The company expects to focus on areas that build its core retail and specialty pharmacy business, leverage its current assets through capital-efficient businesses, and expand its relationships with business partners.

Industry Context

The retail pharmacy industry is facing challenges such as reimbursement pressure, changing consumer behavior, and increased competition.

Comparison to Industry Standards

• CVS Health and Rite Aid are major competitors in the retail pharmacy space.
• CVS Health has been expanding its healthcare services, similar to Walgreens' efforts with VillageMD.
• Amazon's entry into the pharmacy market with Amazon Pharmacy poses a competitive threat to traditional players.

Legal Proceedings

• The Company remains a defendant in multiple actions in federal courts alleging claims generally concerning the impacts of widespread opioid abuse, which have been commenced by various plaintiffs.
• The Company is defending a number of claims, lawsuits, and investigations alleging that the Company's retail pharmacies overcharged for prescription drugs by not submitting the correct usual and customary price during the claims adjudication process.
• On January 16, 2025, the Company filed suit against the DOJ, the DEA, and others seeking a declaratory judgment and other relief in connection with the DEAs attempt to enforce certain purported rules related to the dispensing of opioids and other controlled substances that had never undergone requisite notice-and-comment rulemaking.
• Shortly thereafter, also on January 16, 2025, the DOJ filed suit in the United States District Court for the Northern District of Illinois (Novak vs. Walgreens Boots Alliance, Inc., Case NO. 1:18-cv-05452) against the Company alleging violations of the federal Controlled Substances Act and the federal False Claims Act in dispensing prescriptions for opioids and other controlled substances at its pharmacies nationwide.

Related Party Transactions

• The Company has a long-term pharmaceutical distribution agreement with Cencora pursuant to which the Company sources branded and generic pharmaceutical products from Cencora.
• Additionally, Cencora receives sourcing services for generic pharmaceutical products.
• In connection with the Merger Agreement, the Companys Executive Chairman, Stefano Pessina, and his holding company, who in the aggregate own approximately 17% of the Companys shares of outstanding common stock, entered into a voting agreement in favor of Parent and the Company and a reinvestment agreement with Parent and certain other affiliates of Parent.

Stakeholder Impact

• Shareholders will receive $11.45 per share in cash and a Divested Asset Proceed Right as part of the merger agreement.
• The suspension of the dividend will impact shareholders who rely on dividend income.
• The Footprint Optimization Program will result in store closures, impacting employees and customers in those locations.

Next Steps

• The company intends to complete certain pre-closing transactions at an initial closing that will take place on the business day immediately prior to the closing.
• The company will continue to vigorously defend against any litigation not covered by the Multistate Agreement and other settlement agreements, including private plaintiff litigation.
• The company will continue to explore strategic monetization of non-core assets and other investments to provide additional liquidity.

Key Dates

Keywords

Walgreens Boots Alliance, Merger Agreement, Financial Results, Dividend Suspension, Goodwill Impairment, Footprint Optimization, BrightSpring, Cencora, VillageMD, Pharmacy, Retail